"Giving voice to the needs of the German Medical Marijuana/Cannabis Patient Community" / Cenedella, Patient Advocate since 1977.

English translation of Dr. med. Franjo Grotenhermen article in German Hemp Journal – 13 July 2017 –

Leave a comment

English translation of:

From Dr. med. Franjo Grotenhermen

Typical symptoms of ADHD (attention deficit / hyperactivity disorder) are concentration disorders, internal and external restlessness (“Zappelphilipp”), sleep disturbances and disturbances of the pulse control with anger outbursts. The most commonly used drugs, such as Ritalin and Medikinet, contain methylphenidate, an amphetamine-like substance. Methylphenidate helps many patients, but can increase certain symptoms, such as sleep disorders, aggression and loss of appetite.


Many people with ADHD have mostly discovered that cannabis improves their ability to concentrate, stabilizes the emotional situation, and has a positive impact on school, career and social life in all respects. Many psychiatrists and neurologists, however, reject the treatment of cannabis products or cannabis-based drugs.

This has two main reasons. First of all, members of this professional group often have a strong, negative impression of cannabis, often at the border of the boredom. The fact that cannabis can also be helpful in psychiatric disorders does not fit this picture. ADHD patients have repeatedly told me that psychiatrists and neurologists do not listen to them at all if they want to tell them about their positive experiences. Second, there was not a single controlled clinical trial of cannabis or THC in patients with ADHD by 2017.


The example of a medical certificate issued to one of my patients recently by his neurologist shows which emotions the subject can cause in neurologists. It states that “as a delegate of the BVDN I participated in the consensus conference on the S3 guideline” ADHD in children, adolescents and adults “last on 8.5.17. Regarding the regulation of cannabis, there was (unanimously) the highest degree of recommendation, cannabis should not be used in ADHD ‘. The guideline is expected to be published in the autumn of 2017. This is probably not necessary for the planned certification. You can save money. A Vo. Of cannabis in their case to the health insurance is definitely excluded. ”

BVDN is the professional association of German neurologists. Guidelines from specialists on various diseases help physicians to carry out a rational and scientifically sound diagnosis and therapy. There are generally valid guidelines for the preparation of so-called S3 guidelines. In the case of an S3 guideline, “systematic research, selection and evaluation of scientific evidence (” evidence “) is necessary for the relevant clinical questions” and “every recommendation is discussed within the framework of a structured consensus finding under neutral moderation And whose objectives are the resolution of open decision-making, a final assessment of the recommendations and the measurement of the consensus strength “.


In the above-mentioned participant, I have come to the impression that there is no neutral attitude towards this Sachthema, but a highly emotionalized one.

The S3 guideline for the ADHD may, however, already be ready for the papertonne or at least as far as cannabis is required before its appearance. On May 30, the first clinical study on cannabis in adulthood was published. The participants randomly received either cannabis or a placebo. The results were conducted by researchers at Kings College London and other scientific institutions in the UK.


Cannabis was associated with a significant improvement in hyperactivity / impulsivity, as well as with a trend towards an improvement in lack of attention and emotional instability. The researchers wrote that “adults with ADHD could represent a subgroup of people who experienced a reduction in symptoms and no cognitive impairment after cannabis use.”

Due to the low number of participants, the results are provisional. However, since they are consistent with experience reports from many patients and also from results from an experiment with an animal model of ADHD, they should be taken seriously. For a guideline this would mean that one is cautious with recommendations on cannabis and ADHD. Concluding recommendations in one or other direction are not yet possible.



Philip J. Cenedella IV Over the last 4 decades I have been involved in the fight for patient rights in America, and now here in Germany. I have served as a Board of Director for the World Trade Center San Diego, as a Lead Consultant for Deutsche Telekom's Executive Board, Founded the Dayton Human Trafficking Accords and have been a C-Level Business Development Executive in the technology sector. Since 2016 I have been fulltime in the legal medical marijuana industry, helping companies navigate the biggest potential market in the world. This website is light on details due to confidentiality issues, but be rest assured I am knowledgeable and can assist your growth in some way. Consulting Services: Sales and Business Development Assist with Strategic Direction Professionally represent your firm Licensing and compliance Sales and Distribution networks Qualify potential partners I am your resource, on the ground in Europe! Philip J. Cenedella IV Call +1.888.206.3264 USA + GERMANY Skype: philip.j.cenedella eMail: LinkedIN:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.